Monitoring myeloablative therapy‐induced small bowel toxicity by serum citrulline concentration

Abstract

The simplicity of the method, the low costs, and the lack of drawbacks to the method make the citrulline assay the first choice for measuring and monitoring treatment-related gut damage and provides an objective parameter for cancer treatment-related gut toxicity.